Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Price analytics
Returns
1 day
0.7%
1 week
0.3%
1 month
-1.4%
3 months
24.1%
6 months
56.0%
1 year
-5.5%
3 years
77.1%
Risk
Volatility (1y ann.)
60.0%
Beta vs ASX 200
1.60
Sharpe (1y)
0.12
VaR 95% (1-day)
-4.2%
Max drawdown (1y)
-48.7%
Off 1-year high
-14.2%
Technicals
RSI(14)
43
vs 50DMA
-2.2%
vs 200DMA
26.7%
Trend
Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value1.5
Trailing P/E
0
Forward P/E
4
PEG ratio
—
EV / EBITDA
0
Price / Book
4
Price / Sales
0
Growth47.4
Revenue growth (1y)
0
Revenue CAGR (3y)
100
EPS growth (1y)
0
EPS CAGR (3y)
100
Financial Health100.0
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)47.0
Return on equity
31
Return on assets
26
Operating margin
33
Net margin
100
Cash conversion (OCF / net income)
—
Dividend / Income62.4
Dividend yield (%)
25
Payout ratio
100
FCF dividend cover
—
Momentum81.4
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
39
Position in 52-week range
73
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).